Overview

* Vitalhub ( VHIBF ) Q2 total revenue up 47% YoY to CAD 23.9 mln, beating estimates, per LSEG data

* Adjusted EBITDA rises 50% YoY to CAD 6.3 mln

* Annual recurring revenue grows 55% YoY to CAD 79.6 mln

Outlook

* Company aims to continue international expansion with current cash and ARR

Result Drivers

* ORGANIC GROWTH - Organic ARR growth contributed C$1.9 mln in Q2, reflecting ongoing expansion efforts

* FOREIGN EXCHANGE - ARR benefited from C$170,566 gain due to favorable foreign exchange rate fluctuations

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat C$23.90 C$22 mln

Revenue mln (9

Analysts

)

Q2 C$6.30

Adjusted mln

EBITDA

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Vitalhub Corp ( VHIBF ) is C$15.00, about 9.4% above its August 7 closing price of C$13.59

* The stock recently traded at 58 times the next 12-month earnings vs. a P/E of 46 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)